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ABSTRACT
Older adults (aged 65 years and older) diagnosed with cancer
account for most cancer-related morbidity and mortality in the
United States but are often underrepresented on clinical trials.
Recent attention from a variety of professional, research, regula-
tory, and patient advocacy groups has centered on data linkage
and data sharing as a means to capture patient information and
outcomes outside of clinical trials to accelerate progress in the
fight against cancer.The development of a more robust observa-
tional research data infrastructure would help to address gaps
in the evidence base regarding optimal approaches to treating
cancer among the growing and complex population of older
adults. To demonstrate the feasibility of building such a
resource, we linked information from a sample of older adults
with cancer in North Carolina using three distinct, but com-
plementary, data sources: (a) the Carolina Senior Registry, (b)
the North Carolina Central Cancer Registry, and (c) North Car-
olina fee-for-service Medicare claims data. A description of
the linkage process, metrics, and characteristics of the final
cohort is reported. This study highlights the potential for data
linkage to improve the characterization of health status
among older adults with cancer and the possibility to conduct
passive follow-up for outcomes of interest over time. Exten-
sions of these linkage efforts in partnership with other insti-
tutions will enhance our ability to generate evidence that can
inform the management of older adults with cancer. The
Oncologist 2017;22:1002–1005
INTRODUCTION
Progress in the fight against cancer has relied heavily on evi-
dence generated from clinical trials, representing the experi-
ence of less than 5% of all newly diagnosed cancer patients [1].
Older adults (age 651 years) are disproportionately affected by
this trial-driven research paradigm, as they are less likely than
younger patients to be enrolled onto clinical trials [1, 2] despite
accounting for the majority of cancer-related morbidity and
mortality in the United States [3].
National efforts led by the American Society of Clinical
Oncology (ASCO), the National Cancer Institute, the Food and
Drug Administration, and most recently by former Vice Presi-
dent Joe Biden and the Cancer Moonshot initiative, have pro-
moted data linkage and data sharing as a means to capture
patient information and outcomes outside of clinical trials to
accelerate progress in the fight against cancer. In a recent posi-
tion statement on improving the evidence base for treating
older adults [4], ASCO recommended developing a robust
research infrastructure outside of clinical trials using observa-
tional methods and collection of relevant geriatric oncology-
specific information alongside other patient, tumor, and treat-
ment data.
To demonstrate the feasibility of building such a resource
for geriatric oncology, we linked information from a sample of
older adults with cancer in North Carolina using three distinct
data sources.
MATERIALS AND METHODS
The Carolina Senior Registry (NCT01137825) is a hospital-based
cancer registry including one academic and seven community
sites, started in 2009 to collect data from a brief geriatric
assessment performed on older adults living with cancer [5],
modeled after the tool developed by Hurria and colleagues [6].
Geriatric assessment data were collected through healthcare
provider evaluation (performed by the treating oncologist or
trained clinical research assistant) and patient-administered
questionnaires. The current study is limited to patients treated
at the one academic site, accounting for 69% of all patients in
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the Carolina Senior Registry, as all required data elements for
the linkage were readily available.
Using patients’ first and last name, date of birth, sex, and
hashed social security number, we applied deterministic and
probabilistic linkage algorithms to patients in the Carolina Senior
Registry and the North Carolina Central Cancer Registry
(NCCCR), which captures tumor information legally reportable
by all healthcare providers in North Carolina. We then used a
crosswalk developed by UNC Lineberger Integrated Cancer
Information and Surveillance System researchers to map
patients in the NCCCR to the Medicare enrollment database [7].
Medicare fee-for-service claims capture longitudinal information
about beneficiaries’ healthcare encounters, including diagnoses
and procedures from hospitalizations and outpatient visits.
Figure 1 provides an overview of the information contrib-
uted by each data source. Analyses were conducted using SAS
version 9.4 (Cary, North Carolina). Descriptive statistics for the
cohort are presented. This study was approved by the Institu-
tional Review Board at the University of North Carolina at
Chapel Hill.
RESULTS
Of the 703 older cancer patients in the Carolina Senior Registry,
we linked 636 patients (90%) to the NCCCR and 546 (78%) to
the Medicare enrollment database. Among this population,
369 (68%) were continuously enrolled in Medicare Parts A and
B (without managed care enrollment) for 6 months prior to the
geriatric assessment date. Characteristics of the study popula-
tion stratified by claims-based Charlson comorbidity score [8]
are reported in Table 1.
The study population primarily includes women, driven
largely by overrepresentation of early-stage breast cancer
patients seen by recruiting oncologists. Median age was 74
years, and more than half of the population had some college
education. The prevalence of patients with unintentional
weight loss, prolonged Timed-Up and Go (less than14 sec-
onds, indicating poor mobility), or a physician-rated Karnof-
sky Performance Status of less than 80% steadily increased
with a higher Medicare claims-based Charlson comorbidity
score. However, the prevalence of patients with polyphar-
macy (91 medications) or a Blessed Orientation Memory
Concentration test score of less than 11 (suggestive of mem-
ory impairment) did not monotonically increase with higher
Charlson comorbidity score. These preliminary results dem-
onstrate how linked data resources enrich our ability to iden-
tify important variation in health status among older adults
with cancer that cannot be described using a singular
measure.
Figure 1. Patient information contained in each of the three data sources used in the linkage feasibility study of older adults with cancer
in North Carolina.
Abbreviations: ER, emergency room; NC, North Carolina; NCCCR, North Carolina Central Cancer Registry.
Lund, Meyer, Deal et al. 1003
www.TheOncologist.com Oc AlphaMed Press 2017
DISCUSSION
We demonstrated the feasibility of linking information from
three disparate but complimentary data sources for a sample of
older adults with cancer treated at a North Carolina academic
medical center. This data resource richly characterized the
health status and tumor features of older adults living with can-
cer and established a mechanism to identify specific treatments
administered and conduct passive surveillance and longitudinal
Table 1. Characteristics of sample of older adults, overall and by Charlson Comorbidity Index
Charlson Comorbidity Index (CCI)
calculated from Medicare claims
Characteristics Overall CCI5 0 CCI5 1 CCI5 21
Carolina Senior Registry Data, n 369 251 70 48
Time of geriatric assessment
Within 90 days from cancer diagnosis, n (%) 133 (36) 88 (35) 26 (37) 19 (40)
90–365 days from cancer diagnosis, n (%) 75 (20) 46 (18) 15 (21) 14 (29)
>365 days from cancer diagnosis, n (%) 161 (44) 117 (47) 29 (41) 15 (31)
Age at geriatric assessment, mean (range) 74 (65–100) 74 (65–100) 74 (66–94) 75 (66–93)
65–70 years, n (%) 132 (36) 96 (38) 23 (33) 13 (27)
70–74 years, n (%) 110 (30) 73 (29) 22 (31) 15 (31)
751 years, n (%) 127 (34) 82 (33) 25 (36) 20 (42)
Sex
Male, n (%) 90 (24) 53 (21) 21 (30) 16 (33)
Female, n (%) 279 (76) 198 (79) 49 (70) 32 (67)
Race
White, n (%) 323 (88) – – –
Non-White, n (%) 45 (12) – – –
Highest educational level
High school degree or less*, n (%) 174 (47) 107 (43) 39 (56) 28 (58)
Some college education, n (%) 195 (53) 144 (57) 31 (44) 20 (42)
Body mass index, median (IQR) 26 (23, 30) 26 (23, 30) 26 (23, 30) 28 (25, 32)
Selected geriatric assessment measures
Physical function score, median (IQR) 15 (10, 18) 16 (12, 19) 11 (7, 16) 8 (5, 16)
BOMC 11, median (IQR) 4 (2, 6) 2 (2, 6) 2 (2, 6) 6 (2, 8)
MHI 13 12 or anxious (depressed), n (%) 60 (16) – – –
MHI 13 6 (anxious), n (%) 88 (24) 56 (22) 18 (26) 14 (29)
Daily medications (9 medications), n (%) 143 (39) 83 (33) 36 (51) 24 (50)
Reported falls in past 6 months (11 fall), n (%) 88 (24) 50 (20) 16 (23) 16 (33)
Unintentional weight loss 5%, n (%) 80 (22) 41 (16) 20 (29) 19 (40)
TUG 14 seconds (or unable), n (%) 113 (31) 64 (25) 26 (37) 23 (48)
Physician-rated KPS 80%, n (%) 43 (12) 16 (6) 14 (20) 13 (27)
NCCCR Data
Cancer site
Breast, n (%) 194 (53) 152 (61) 29 (41) 13 (27)
Hematologic malignancies, n (%) 47 (13) 25 (10) 11 (16) 11 (23)
Other, n (%) 128 (35) 74 (29) 30 (43) 24 (50)
AJCC Stage 6th Edition, n (%)
0–II, n (%) 198 (54) 148 (59) 29 (41) 21 (44)
III–IV, n (%) 120 (33) 74 (29) 30 (43) 16 (33)
Missing or unstaged, n (%) 51 (14) 29 (12) 11 (16) 11 (23)
Medicare Enrollment and Claims Data
Deaths, n (%) 92 (25) 53 (21) 24 (34) 15 (31)
Number of months from GA to death or 12/31/2013, median (IQR) 19 (7, 34) 23 (11, 38) 13 (5, 27) 12 (5, 23)
aIndicates that missing values were added to this category.
Abbreviations: –, at least one cell size was less than 11 and therefore had to be suppressed for confidentiality; AJCC, American Joint Commission
on Cancer; BOMC, Blessed Orientation Memory Concentration test; CCI, Charlson Comorbidity Index; KPS, Karnofsky Performance Score; GA, geri-
atric assessment; IQR, interquartile range; MHI, Mental Health Index; TUG, Timed-Up and Go.
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follow-up using Medicare enrollment and claims data. As cancer
treatment regimens become increasingly complex, both regula-
tors and patient advocacy groups want to better understand
the impact of treatment on patient-centered geriatric oncology
outcomes (e.g., emergency department visits, nursing home
placement, decline in physical function, memory impairment),
which are not traditionally captured in clinical trials. Therefore,
linkage of rich but disparate data sources represents a promising
avenue to capturemoremultifaceted outcomemeasures.
Other groups have launched research initiatives to improve
the evidence base for treating older adults with cancer or col-
lect real-world data on cancer patients outside of the trial set-
ting. For example, the Cancer and Aging Research Group has
undertaken numerous studies collecting geriatric assessment
data on patients from multiple medical centers [9]. However,
these data have not yet been linked to state cancer registries or
Medicare, Medicaid, or other insurance claims data, limiting
their ability to passively follow patients over time. On the other
hand, researchers within the Cancer Research Network have
developed a robust infrastructure for pooling electronic health
record data for cancer patients across multiple integrated
healthcare delivery systems [10], but detailed geriatric assess-
ment data are not routinely collected for older patients with
cancer in these settings.
CONCLUSION
While the research questions that can be explored using the
linked Carolina Senior Registry data are limited by the small
sample and limited generalizability at present, we plan to part-
ner with institutions interested in conducting similar linkages in
order to build a larger database well-suited to address a variety
of questions regarding the care of older adults with cancer. In
the future, large, linked data sources can be used to fill existing
evidence gaps regarding long-term benefits and harms of
cancer treatments, and ultimately to tailor the delivery of can-
cer care and improve outcomes for older adults with cancer.
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